Umeclidinium bromide

A medication used in the management of chronic obstructive pulmonary disease

Umeclidinium bromide
Umeclidinium bromide
Chemical nomenclature
IUPAC name	(1R,2R,4S,5S)-4-[(hydroxydi-2-thienylacetyl)oxy]-1-azoniabicyclo[2.2.2]octane bromide

Umeclidinium bromide is a medication used in the management of chronic obstructive pulmonary disease (COPD). It is a long-acting muscarinic antagonist (LAMA) that helps to open the airways and make breathing easier.

Medical uses

Umeclidinium bromide is primarily used as a maintenance treatment for COPD. It is not indicated for the relief of acute bronchospasm or for the treatment of asthma. The medication is administered via inhalation, typically once daily, using a specific inhaler device.

Mechanism of action

Umeclidinium bromide works by blocking the action of acetylcholine on muscarinic receptors in the airways. This action leads to the relaxation of bronchial smooth muscle, resulting in bronchodilation and improved airflow in patients with COPD.

Side effects

Common side effects of umeclidinium bromide include dry mouth, cough, and upper respiratory tract infections. Less common but more serious side effects can include urinary retention and paradoxical bronchospasm.

Pharmacokinetics

After inhalation, umeclidinium bromide is absorbed into the bloodstream, where it reaches peak plasma concentrations within a few hours. It is metabolized primarily by the liver and excreted in the urine and feces.

History

Umeclidinium bromide was developed by GlaxoSmithKline and was approved for medical use in the United States in 2013. It is often combined with other medications, such as vilanterol, to enhance its therapeutic effects.

Related pages

• Chronic obstructive pulmonary disease
• Muscarinic antagonist
• GlaxoSmithKline

References

• 
  Chemical structure of Umeclidinium bromide
• 3D model of Umeclidinium bromide
  3D model of Umeclidinium bromide